Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Information Regarding Operating Segment

Detailed information regarding our single operating segment’s significant revenues, expenses and operating loss is as follows:

	Year Ended December 31,
(in thousands)	2025		2024		2023
Revenues
Product sales, net	$	377,808	$	319,196	$	82,526
Other revenues(1)	29,512		14,419		41,930
Total revenues	407,320		333,615		124,456
Less
Cost of product sales(2)	11,185		6,851		2,323
Other cost of revenue(3)	28,352		43,705		15,472
Research and development(4)	58,429		39,480		29,231
Selling(4)	226,925		162,957		80,028
General and administrative(4)	58,662		52,916		34,020
Stock-based compensation	48,962		37,381		13,530
Other segment expenses(5)	15,782		18,275		13,128
Total costs and operating expenses	448,297		361,565		187,732
Consolidated loss from operations	(40,977)		(27,950)		(63,276)
Other reconciliation items(6)	(20,622)		(11,186)		(2,791)
Consolidated net loss	$	(61,599)	$	(39,136)	$	(66,067)

(1)Other revenues includes revenues from our collaboration partnerships, including licensing revenue, product supply revenue and non-cash royalty revenue related to the sale of future royalties.

(2)Cost of product sales includes the cost of commercial goods sold to our Customers, such as the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process and indirect overhead costs.

(3)Other cost of revenue includes the cost of materials sold to our collaboration partners under product supply agreements, certain costs related to capacity expansion at current and future CMOs and payments due to AstraZeneca. As of the end of the 2025 second quarter, the maximum $75.0 million royalty obligation under the AstraZeneca Termination Agreement had been fully recognized.

(4)Research and development, selling and general administrative expenses herein do not include certain allocated items, such as stock-based compensation expenses.

(5)Other segment expenses primarily consists of allocated facilities, information technology, and employee costs of approximately $14.8 million, $16.9 million and $12.3 million in 2025, 2024 and 2023, respectively.

(6)Other reconciliation items includes interest expense, non-cash interest expense related to the sale of future royalties, provision for income taxes and other income, net.